The 2024 edition of Clarivate’s Drugs to Watch features 13 drugs that highlight an inflection point where amazing, merging tech is finally paying off with ADCs and CRISPR/Cas9 and bispecifics, Matthew Arnold, principal analyst, Clarivate Life Sciences and Healthcare, told BioWorld.
The 2024 edition of Clarivate’s Drugs to Watch features 13 drugs that highlight an inflection point where amazing, merging tech is finally paying off with ADCs and CRISPR/Cas9 and bispecifics, Matthew Arnold, principal analyst, Clarivate Life Sciences and Healthcare, told BioWorld.
Six months out from the World Health Organization ending the global health emergency brought on by the pandemic, there’s no need for the World Trade Organization to expand a five-year intellectual property (IP) waiver for vaccines to COVID-19-related drugs, devices and diagnostics.
